A Study of XmAb®18087 in Subjects With NET and GIST

Completed · Phase 1

Conditions studied: Neuroendocrine Tumor, Gastrointestinal Neoplasm

In brief

This is a Phase 1, multiple dose, ascending dose escalation study; to define a MTD/RD and regimen consisting of a first "priming" dose and escalated subsequent doses of XmAb18087; to describe safety and tolerability; to assess PK and immunogenicity; and to preliminarily assess anti-tumor activity of XmAb18087 in subjects with advanced NET or GIST. The study will enroll dosing cohorts to establish a MTD/RD and regimen in subjects with advanced NET or GIST, then enroll additional subjects into separate NET and GIST expansion cohorts to collect additional data on safety and potential efficacy of XmAb18087.

Key facts

Study ID: NCT03411915
Run by: Xencor, Inc.
People needed: 62
Starts: 2018-01-22
Expected to finish: 2021-10-26
Last updated by the study team: 2022-05-10

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Histologically or cytologically confirmed well differentiated low or intermediate grade (World Health Organization [WHO] Grade 1 or 2) NET of pancreatic, gastrointestinal, lung, or undetermined origin that is locally advanced or metastatic and has progressed within the past 12 months
Histologically confirmed GIST that is locally advanced or metastatic
NET and GIST tumors must be unresectable
NET subjects must have progressed on or been ineligible for treatment with somatostatin analogues (SSA) and at least one other FDA-approved targeted therapy (everolimus or sunitinib).
GIST subjects must have previously received all FDA-approved therapies (imatinib mesylate, sunitinib malate, and regorafenib) for which they are eligible
Must have disease measurable by RECIST 1.1 criteria using either computed tomography (CT) or magnetic resonance imaging (MRI) scan
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

You may not qualify if…

Diagnosis of high-grade (WHO Grade 3) or poorly differentiated NET; high-grade neuroendocrine carcinoma; large cell neuroendocrine carcinoma, small cell carcinoma, or mixed small and large cell carcinoma.
Subjects currently receiving anti-cancer therapies (other than SSAs, which may continue).
Subjects who have received anti-cancer therapies within 2 weeks of the start of study drug (including chemotherapy, radiation therapy, immunotherapy, etc.).
Must not be experiencing a Grade 3 or 4 toxicity from previous anti-cancer treatment
Must not be receiving other anti-cancer therapies (except somatostatin analogues, which may be allowed)
Must not have poorly controlled diabetes mellitus, known central nervous system involvement by malignant disease or insufficient bone marrow, renal, or hepatic function

Where it is running

Mayo Clinic — Phoenix, Arizona, United States
City of Hope Medical Center — Duarte, California, United States
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute — Los Angeles, California, United States
Stanford Cancer Center — Palo Alto, California, United States
University of Colorado, Anschutz Medical Campus — Aurora, Colorado, United States
Mayo Clinic — Jacksonville, Florida, United States
H. Lee Moffitt Cancer Center & Research Institute — Tampa, Florida, United States
Emory University — Atlanta, Georgia, United States
Northwestern Medicine — Chicago, Illinois, United States
Dana-Farber Cancer Institute — Boston, Massachusetts, United States
Mayo Clinic — Rochester, Minnesota, United States
Memorial Sloan Kettering Cancer Center — New York, New York, United States
James Cancer Center — Columbus, Ohio, United States
University of Pennsylvania, Abramson Cancer Center — Philadelphia, Pennsylvania, United States
MD Anderson Cancer Center — Houston, Texas, United States
University of Virginia — Charlottesville, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.